Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype
Deborah M Stephens, Amy Stark, Jeffrey A. Jones et al.
Key Points:
Retrospective review of 17p- pts on clinical trials who underwent successful treatment with novel agents (ibrutinib) or cyclin-dependent kinase inhibitors.
PFS significantly extended with IB and CDKi compared to other therapies.
Implications:
- Authors demonstrated that treatment of 17p- CLL pts with IB and CDKi at OSU improved response, PFS, and OS.
View the original abstract on the ASH website.
